Company intelligence / Profile preview

Horizon Therapeutics

Ownership: Private
Employees: ~2000
Development stage: Commercial

Overview

Horizon Therapeutics was a biopharmaceutical company focused on developing and commercializing medicines primarily for rare autoimmune and severe inflammatory diseases. Its most notable products included Tepezza, Krystexxa, Actimmune, Ravicti, Duexis, Rayos/Lodotra, Uplizna among others. The company grew rapidly through strategic acquisitions of both marketed drugs and late-stage assets. Tepezza became the first FDA-approved treatment for thyroid eye disease in January 2020 with strong clinical efficacy (~80% improvement rate), driving significant revenue growth prior to its acquisition by Amgen in October 2023.

Therapeutic areas: Metabolic DisordersRheumatologyEndocrinologyRare DiseasesNeurology
Modalities: Small moleculesMonoclonal antibodies (mAbs)Enzyme therapiesOral therapeutics
Industry: Biotech

Drug pipeline

3 assets

teprotumumab

Commercial

Indications: Thyroid eye disease

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Horizon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Horizon Therapeutics.

Explore the full profile